Evidence map›Paper›PMID 35717719›Full record

ArticleJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association2022

Synergistic Neuroprotection by a PAF Antagonist Plus a Docosanoid in Experimental Ischemic Stroke: Dose-Response and Therapeutic Window.

Madigan M Reid, Andre Obenaus, Pranab K Mukherjee, Larissa Khoutorova, Cassia R Roque, Nicos A Petasis, Reinaldo B Oria, Ludmila Belayev, Nicolas G Bazan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Neuroprotectants: The Next Frontier in Neurology.Journal of pharmacy & bioallied sciences · 2026
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Madigan M ReidNeuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA. Electronic address: mreid1@lsuhsc.edu.
Andre ObenausDepartment of Pediatrics, School of Medicine, University of California, Irvine, CA, USA. Electronic address: obenausa@hs.uci.edu.
Pranab K MukherjeeNeuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA. Electronic address: pmukhe@lsuhsc.edu.
Larissa KhoutorovaNeuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA. Electronic address: lkhout@lsuhsc.edu.
Cassia R RoqueLaboratory of the Biology of Tissue Healing, Ontogeny and Nutrition, Department of Morphology and Institute of Biomedicine, School of Medicine, Federal University of Ceara, Fortaleza, Brazil.
Nicos A PetasisDepartment of Chemistry, University of Southern California, Los Angeles, CA, USA. Electronic address: petasis@usc.edu.
Reinaldo B OriaLaboratory of the Biology of Tissue Healing, Ontogeny and Nutrition, Department of Morphology and Institute of Biomedicine, School of Medicine, Federal University of Ceara, Fortaleza, Brazil. Electronic address: oria@ufc.br.
Ludmila BelayevNeuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA. Electronic address: lbelay@lsuhsc.edu.
Nicolas G BazanNeuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA. Electronic address: nbazan@lsuhsc.edu.
Louisiana State University Health Sciences Center New Orleans · USUniversidade Federal do Ceará · BRUniversity of California, Irvine · USUniversity of Southern California · US

Funding

Docosanoids modulate homeostasis and cell survival after ischemic strokeR01NS109221 · NINDS · LSU HEALTH SCIENCES CENTER · PI BAZAN, NICOLAS G., BELAYEV, LUDMILA S. · 2019 to 2023
$1.7M
Novel combinatory therapy for experimental ischemic strokeR01NS104117 · NINDS · LSU HEALTH SCIENCES CENTER · PI BAZAN, NICOLAS G., BELAYEV, LUDMILA S. · 2018 to 2022
$1.6M
NINDS NIH HHS R01 NS104117NINDS NIH HHS R01 NS109221
6 · The paper itself

Abstract

objectiveWe tested the hypothesis that blocking pro-inflammatory platelet-activating factor receptor (PAFR) with LAU-0901 (LAU) plus administering a selected docosanoid, aspirin-triggered neuroprotectin D1 (AT-NPD1), which activates cell-survival pathways after middle cerebral artery occlusion (MCAo), would lead to neurological recovery. Dose-response and therapeutic window were investigated. MATERIALS AND

methodsMale SD rats were subjected to 2 hours of MCAo. Behavior testing (days 1-7) and ex vivo MRI on day 7 were conducted. In dose-response, rats were treated with LAU (45 and 60 mg/kg; IP), AT-NPD1 (111, 222, 333 µg/kg; IV), LAU+AT-NPD1 (LAU at 3 hours and AT-NPD1 at 3.15 hours) or vehicle. In the therapeutic window, vehicle, LAU (60 mg/kg), AT-NPD1 (222 µg/kg), and LAU+AT-NPD1 were administered at 3, 4, 5, and 6 hours after onset of MCAo.

resultsLAU and AT-NPD1 treatments alone improved behavior by 40-42% and 20-30%, respectively, and LAU+AT-NPD1 by 40% compared to the vehicle group. T2-weighted imaging (T2WI) volumes were reduced with all doses of LAU and AT-NPD1 by 73-90% and 67-83% and LAU+AT-NPD1 by 94% compared to vehicle. In the therapeutic window, LAU+AT-NPD1, when administered at 3, 4, 5, and 6 hours, improved behavior by 50, 56, 33, and 26% and reduced T2WI volumes by 93, 90, 82, and 84% compared to vehicle.

conclusionsWe have shown here for the first time that LAU plus AT-NPD1 treatment affords high-grade neuroprotection in MCAo, equaling or exceeding that afforded by LAU or AT-NPD1 alone at considerably moderate doses. It has a broad therapeutic window extending to 6 hours after stroke onset.

Indexed as

Ischemic StrokeNeuroprotective AgentsStrokeAnimalsAspirinInfarction, Middle Cerebral ArteryMaleNeuroprotectionRatsRats, Sprague-DawleyAspirinNeuroprotective AgentsAT-NPD1BehaviorLAU-0901MCAoMRIPenumbra

Identifiers

PMID35717719
PMCPMC9976619
OpenAlexW4283031834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.